Response and progression-free survival are unreliable in providing signals of benefit of new agents, especially immunotherapy, in nonrandomized phase 2 trials of salvage therapy for metastatic urothelial carcinoma. A nomogram that used baseline prognostic variables was developed to estimate the 12-month survival of patients receiving salvage chemotherapy to which observed survival of nonrandomized data sets could be compared to interpret results. Introduction: Optimal end points in phase 2 trials evaluating salvage therapy for metastatic urothelial carcinoma are necessary to identify promising drugs, particularly immunotherapeutics, where response and progression-free survival may be unreliable. We developed a nomogram using data from phase 2 trials of historical agents to estimate the 12-month overall survival (OS) for patients to which observed survival of nonrandomized data sets receiving immunotherapies could be compared. Patients and Methods: Survival and data for major prognostic factors were obtained from phase 2 trials: hemoglobin, performance status, liver metastasis, treatment-free interval, and albumin. A nomogram was developed to estimate 12-month OS. Patients were randomly allotted to discovery:validation data sets in a 2:1 ratio. Calibration plots were constructed in the validation data set and data bootstrapped to assess performance. The nomogram was tested on external nonrandomized cohorts of patients receiving pemetrexed and atezolizumab. Results: Data were available from 340 patients receiving sunitinib, everolimus, docetaxel þ vandetanib, docetaxel þ placebo, pazopanib, paclitaxel, or docetaxel. Calibration and prognostic ability were acceptable (c index ¼ 0.634; 95% confidence interval [CI], 0.596-0.652). Observed 12-month survival for patients receiving pemetrexed (n ¼ 127, 23.5%; 95% CI, 16.2-31.7) was similar to 95% CI,; P > .05), while observed results with atezolizumab (n ¼ 403, 39.0%; 95% CI, 34.1-43.9) exceeded predicted results (24.6%; 95% CI, 23.4-25.8; P < .001). Conclusion: This nomogram may be a useful tool to interpret results of nonrandomized phase 2 trials of salvage therapy for metastatic urothelial carcinoma by assessing the OS contributions of drug intervention independent of prognostic variables.
Introduction
Taxanes have been historically used for postplatinum salvage therapy in the United States, but their use yields dismal outcomes, with responses in about 10% of patients and median progressionfree survival (PFS) and overall survival (OS) of 2 to 3 months and 5 to 8 months, respectively. 1, 2 Vinflunine was approved in other countries on the basis of extension of survival compared to best supportive care in the trial-eligible population. 3 Outcomes with vinflunine appear similar to taxanes, with the caveat of comparison across trials. 3 Multiple agents have been evaluated for improving outcomes of metastatic urothelial carcinoma (mUC) patients in the salvage setting, mostly in nonrandomized phase 2 trials. [4] [5] [6] [7] More recently, the programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have been investigated mostly in nonrandomized phase 2 trials. Indeed, atezolizumab, nivolumab, durvalumab, and avelumab have been granted accelerated approval by the US Food and Drug Administration was based on durable response rates of 15% to 20% observed in nonrandomized phase 2 trials, and full approval has been granted to pembrolizumab on the basis of survival benefit versus chemotherapy in a phase 3 trial. [8] [9] [10] [11] [12] Evaluating the clinical benefit of PD-1 and PD-L1 inhibitors in the context of nonrandomized phase 2 trials is challenging. Early analysis of clinical benefit seen with chemotherapy (ie, response rates, PFS, and median survival) has not indicated it to be accurately predictive of long-term survival. Moreover, patients receiving salvage therapy exhibit a spectrum of outcomes influenced by pretreatment prognostic factors. Thus, it is critical in the interpretation of noncomparative trials that favorable long-term outcomes reported in such studies is a function of the drug intervention and not solely due to patients with more favorable prognostic features.
We hypothesized that the ability to predict survival at a landmark time point beyond the usual median OS may capture delayed benefits and assist in interpreting long-term survival outcomes observed in nonrandomized phase 2 trials of new agents, especially immunotherapy. Previously, we identified and validated a 5-factor model that improved the prognostication of patients receiving salvage therapy with taxanes and other historically evaluated agents with similar activity. 13 We sought to improve the utility of these prognostic factors by constructing a nomogram utilizing these factors to predict 12-month OS of a cohort of patients receiving taxanes and other historical salvage agents studied in phase 2 trials, all of which had similar outcomes. We then applied this nomogram to external data sets for further validation of the model and to assess the benefit from pemetrexed or atezolizumab compared to nomogram-predicted survival.
Patients and Methods

Patient Selection
Prospective phase 2 trials of salvage systemic chemotherapy and/ or biologic agent therapy (not including PD-1/PD-L1 inhibitors) used in our previous analyses to construct prognostic models for patients after platinum-based chemotherapy for mUC were pooled. All of these trials required previous pathologic confirmation of urothelial carcinoma and progressive disease with measurable lesions. Trials that administered taxanes or other agents considered to have modest activity similar to taxanes were selected. Trials were also selected on the basis of the availability of individual patientlevel data and the ability of the respective investigators to provide these data. Data regarding survival and the 5 previously validated prognostic factors were required and collected: albumin, treatmentfree interval (TFI), hemoglobin (Hb), Eastern Cooperative Oncology Group performance status (ECOG PS), and liver metastasis status. The data were deidentified. These trials were approved by the institutional review boards of the respective institutions.
Construction of Validated Nomogram
The patients were randomly (2:1) split into discovery and validation data sets. A nomogram using the 5 clinical prognostic factors was developed to estimate 12-month survival in the discovery data set and externally validated in the validation data set. The 95% biascorrected and accelerated confidence intervals were constructed using 2000 bootstrap samples. Calibration and prognostic ability were assessed by comparing estimated versus observed 12-month OS. Concordance was measured using the concordance index. Analyses were performed by SAS 9.0 (SAS Institute, Cary, NC) or R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/).
Application of Nomogram to External Data Sets
The nomogram was applied to external nonrandomized salvage therapy data sets: a single-center retrospective cohort of patients receiving pemetrexed and another data set 8, 12, 14, 15 composed of a combination of 2 single-arm trials of atezolizumab (PCD4989g and IMvigor210). Expected 12-month survival was calculated on the basis of the nomogram for each patient, and the observed 12-month survival was estimated by the Kaplan-Meier method. The difference between the observed and expected 12-month observed survival was then compared across bootstrap samples by a paired t test.
Results
Patient Characteristics
Data were available from 340 patients receiving docetaxel þ vandetanib or placebo (n ¼ 109), sunitinib (n ¼ 77), everolimus (n ¼ 45), pazopanib (n ¼ 42), paclitaxel (n ¼ 36), and docetaxel (n ¼ 31). 4, 6, [16] [17] [18] [19] The discovery data set consisted of 227 patients, and the validation data set included 113 patients (Table 1) .
Construction and Performance of Nomogram
The nomogram, consisting of the 5 prognostic factors, was constructed from the discovery or development data set ( Figure 1 ). The performance of the nomogram was assessed in the validation data set ( Table 2 ). The estimated 12-month survival was segregated into tertiles, and estimated versus observed 12-month survivals were compared in the validation data set ( Figure 2 ). Calibration and prognostic ability of the model were acceptable in the validation cohort (c index ¼ 0.634; 95% confidence interval [CI], 0.596-0.652). Additionally, the c index was applied to the separate pemetrexed data set because this agent demonstrates similar outcomes as agents included in the primary discovery and validation data sets above; the c index was 0.634 (95% CI, 0.548-0.642).
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Use of Nomogram to Compare Predicted Versus Observed 12-Month Survival in External Data Sets
The nomogram was applied to external data sets: pemetrexed (n ¼ 127) and a data set of patients receiving atezolizumab (n ¼ 403) composed of two single-arm trials (PCD4989g [n ¼ 93] and IMvigor210 [n ¼ 310]) (Table 2, Figure 3 ). The c index was 0.759 for the PCD4989g data set and 0.690 for the IMvigor210 data set. Observed 12-month survival for patients receiving pemetrexed (23.5%; 95% CI, 16.2-31.7) was similar to nomogram-predicted survival (19%; 95% CI, 16.5-21.5; P > .05). In contrast, the observed 12-month survival with atezolizumab (46.9%, 95% CI, 35.7-57.6, for PCD4989g, and 36.9%, 95% CI, 31.6-42.6, for IMvigor210) significantly exceeded predicted results (24.9%, 95% CI, 22.4-27.5, for PCD4989g, and 24.6%, 95% CI, 23.2-26.0, for IMvigor210; P < .001 for both studies). The observed result with the combination of 
Figure 1 Nomogram to Estimate 12-Month Survival Based on Baseline Prognostic Factors
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; Hb ¼ hemoglobin; LLN ¼ lower limit of normal; OS ¼ overall survival; TFI ¼ treatment-free interval.
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Clinical Genitourinary Cancer August 2018 -e963 the 2 atezolizumab data sets (39.0%; 95% CI, 34.1-43.9) also exceeded the predicted result (24.6%; 95% CI, 23.4-25.8; P < .001).
Discussion
Separating the effect on survival with novel drugs from the effect of preexisting prognostic factors in noncomparative trials is not possible as a result of patient heterogeneity and marked variability of prognostic factors across trials. Although phase 3 trials that control for known prognostic factors across arms remain the reference standard, there is a compelling need for an intermediate methodology to assess clinical benefit seen in nonrandomized phase 2 trials. Nomograms can predict individual patient outcome by incorporating a weighted contribution of each prognostic factor, and they have been used to predict individualized risk estimates for 1-, 2-, and 5-year survival of mUC patients treated with first-line chemotherapy. 20, 21 This study has extended the nomogram methodology to the postplatinum setting by incorporating 5 baseline prognostic factors (albumin, Hb, ECOG PS, TFI, and liver metastasis), providing 12-month survival estimates and demonstrating its usefulness in identifying the survival benefit from novel drugs. Thus, the nomogram facilitates the interpretation of nonrandomized salvage therapy data and comparison of results across trials, especially in the era of immunotherapy. While trials report baseline characteristics, they frequently vary across trials, and all 5 validated prognostic factors are not always reported, which renders comparison of outcomes across trials problematic, while the application of our nomogram allows the rigorous comparison of observed versus expected survival after controlling for each factor in individual patients. This trial-specific nomogram was validated using a randomized internal cohort of patients and then applied to two external data sets of patients, one that received pemetrexed and another cohort of trial patients receiving atezolizumab. Atezolizumab was associated with a significantly longer 12-month survival compared to nomogrampredicted survival, while treatment with pemetrexed showed no survival difference. While the landmark 12-month survival end point was selected to better capture the benefits from immunotherapy, this nomogram was also applicable to interpreting nonrandomized phase 2 trials evaluating other cytotoxic, biologic, and targeted agents.
The estimated 12-month survival rate of the atezolizumab and pemetrexed data sets if these patients had received historical agents is similar to the 12-month survival observed in the control chemotherapy arm of the KEYNOTE-045 phase 3 trial, which compared salvage taxane/vinflunine versus pembrolizumab. 11 The 12-month survival of approximately 40% observed in atezolizumab has also been observed with pembrolizumab in the KEYNOTE-045 trial and can be considered a benchmark when designing future . Hence, application of this nomogram to the nonrandomized phase 2 trials may be especially useful because phase 3 salvage trials of these agents are not planned. Recently, it was reported that the phase 3 IMvigor211 study that compared atezolizumab versus chemotherapy (vinflunine or taxane) for progressive postplatinum mUC patients did not meet its primary end point of superior OS in atezolizumab-treated patients. 24 However, the results observed with atezolizumab in the IMvigor211 study were consistent with those observed in the preceding phase 2 IMvigor210 trial. Specifically, any evidence for imbalances between the arms for known prognostic factors needs scrutiny because the chemotherapy arm appeared to overperform. Furthermore, this trial stratified patients for the older Bellmunt model (which does not include TFI and albumin), chemotherapy agent, and PD-L1 status. 25 The PD-L1 expression by immune cells using the SP142 antibody by this trial has also been demonstrated to be an outlier and exhibits greater variability compared to other assays. 26 Potentially, the statistical design of the trial may have compromised the ability to identify an extension of survival. Notably, the primary end point, OS, was evaluated in a hierarchical fashion in cohorts defined by PD-L1 expression. However, the requirement for the high PD-L1eexpressing population to exhibit an increment in survival may have undermined the ability to identify a benefit in the entire intention to treat population. Thus, the IMvigor211 trial may be an optimal independent data set for potential future analyses that apply this novel nomogram methodology because the prognostic factors used in the nomogram are different than those used for stratification in the trial. Such an analysis may provide broader insight into whether: (1) the prognostic variables for the trial are better than those used in the nomogram methodology, or vice versa; (2) imbalances across treatment arms exist that may not have been evident using conventional stratification; (3) the conventional arm or any individual drug cohort (ie, paclitaxel, docetaxel, or vinflunine) performed better than expected when controlled for nomogram-specific prognostic factors; and/or (4) the investigational arm with atezolizumab underperformed as a result of a greater proportion of nomogramspecific poor prognostic factors. Our study has limitations inherent to retrospective studies. Ideally, the nomogram to predict 12-month survival should have included only patients receiving taxanes or vinflunine. However, individual-level data from an adequate number of patients receiving taxanes or vinflunine were not available. Hence, in addition to patients receiving single-agent taxanes, the discovery and validation data sets used data from patients receiving docetaxel plus vandetanib, sunitinib, everolimus, and pazopanib. Nevertheless, the dismal overall outcomes observed in phase 2 trials evaluating sunitinib, everolimus, and pazopanib appear similar to outcomes seen with single-agent taxanes or vinflunine, and it may be considered reasonable to utilize such patients to construct the nomogram. The use of data from patients who received docetaxel combined with vandetanib may be questioned, but it must be noted that this combination did not demonstrate any statistical differences in all end points compared with docetaxel alone in a randomized phase 2 trial. Because the nomogram was constructed using data derived from patients enrolled onto phase 2 trials, its applicability to a retrospectively assembled data set such as the pemetrexed data set or a phase 1 trial data set (PCD4989g) may be questioned. However, the nomogram did control for 5 major baseline prognostic factors. While phase 1 trial patients were more heavily pretreated, we have reported earlier that the number of prior lines of therapy was not independently significant after controlling for other prognostic factors. 27 The salvage chemotherapy trials used to construct the nomogram were completed years before the atezolizumab trials, and the confounding impact of recently improved supportive care may be a potential limitation of comparing the two cohorts. The c index (0.63) may be considered modest, although this is similar to nomograms proposed in other settings, and molecular factors may provide a more optimal c index. Indeed, tumor subtypes based on gene expression and tumor mutation burden may improve our ability to prognosticate. 12 The survival at 12 months cannot be ascertained at an early time point, unlike response and PFS. However, a valuable intermediate end point at an early time point that translates to extension of survival is unclear, especially in the context of immunotherapy. Although durable responses are seen in 15% to 20% of patients, a substantial proportion of patients who experience no response also benefit, as suggested by an improvement in median OS without an improvement in median PFS with pembrolizumab. 11 Our group has previously proposed the use of a nomogram based on baseline prognostic factors to estimate PFS at 6 months to interpret nonrandomized phase 2 trials. 28 However, PFS appears suboptimal to capture benefit from immunotherapy. The application of this nomogram to the other PD-1/PD-L1 inhibitor data sets in the salvage mUC setting is desirable, and such efforts are underway, which will enable interpretation of results across trials and potentially identify promising novel agents. Unfortunately, pharmaceutical companies are unlikely to aim to compare their agents with competing agents manufactured by other companies. While this nomogram may be a useful tool to interpret results of nonrandomized phase 2 trials of salvage therapy for mUC, it cannot replace phase 3 trials as definitive evidence. A novel prognostic model in the setting of salvage PD-1/PD-L1 inhibitors is necessary because different factors may be more relevant in this setting. This would enable the construction of successive generations of nomograms to interpret survival in nonrandomized phase 2 trials to enable virtual comparisons. With the emergence of PD-1/PD-L1 inhibitors as first-line therapy of cisplatin-ineligible patients based on nonrandomized phase 2 trials, nomograms developed in the firstline platinum-based chemotherapy setting may be utilized to interpret these data. 21 Moreover, new nomograms will be necessary in the first-line single-agent PD-1/PD-L1 inhibitor setting to help interpret new regimens that are undergoing nonrandomized phase 2 evaluation in this setting.
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Conclusion
A nomogram was developed incorporating 5 validated baseline prognostic factors to estimate 12-month survival in the context of patients receiving historical agents to treat progressive mUC after platinum-based chemotherapy. The application of this nomogram to nonrandomized data sets of patients receiving pemetrexed or atezolizumab suggested that atezolizumab extends survival compared to historical agents while pemetrexed does not.
Clinical Practice Points
Because response and PFS may be unreliable to identify promising drugs, particularly immunotherapeutics, optimal end points are necessary to interpret results of phase 2 trials evaluating salvage therapy for mUC. We developed a nomogram using data using baseline prognostic factors from phase 2 trials of historical agents to estimate the 12-month OS for patients to which observed survival of nonrandomized data sets receiving immunotherapies could be compared. This nomogram may be a useful tool to interpret results of nonrandomized phase 2 trials of salvage therapy for mUC by assessing the OS contributions of drug intervention independent of prognostic variables.
